APA

Boulangé C. L., Rood I. M., Posma J. M., Lindon J. C., Holmes E., Wetzels J. F. M., Deegens J. K. J. & Kaluarachchi M. R. (20190607). NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor. : Molecular omics.

Chicago

Boulangé Claire L, Rood Ilse M, Posma Joram M, Lindon John C, Holmes Elaine, Wetzels Jack F M, Deegens Jeroen K J and Kaluarachchi Manuja R. 20190607. NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor. : Molecular omics.

Harvard

Boulangé C. L., Rood I. M., Posma J. M., Lindon J. C., Holmes E., Wetzels J. F. M., Deegens J. K. J. and Kaluarachchi M. R. (20190607). NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor. : Molecular omics.

MLA

Boulangé Claire L, Rood Ilse M, Posma Joram M, Lindon John C, Holmes Elaine, Wetzels Jack F M, Deegens Jeroen K J and Kaluarachchi Manuja R. NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor. : Molecular omics. 20190607.